A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat

Clicks: 175
ID: 114385
2011
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #210 of 438 articles by views in acta neuropathologica

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 438 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Incompletely resectable ependymomas are associated with poor prognosis despite intensive radio- and chemotherapy. Novel treatments have been difficult to develop due to the lack of appropriate models. Here, we report on the generation of a high-risk cytogenetic group 3 and molecular group C ependymoma model (DKFZ-EP1NS) which is based on primary ependymoma cells obtained from a patient with metastatic disease. This model displays stem cell features such as self-renewal capacity, differentiation capacity, and specific marker expression. In vivo transplantation showed high tumorigenic potential of these cells, and xenografts phenotypically recapitulated the original tumor in a niche-dependent manner. DKFZ-EP1NS cells harbor transcriptome plasticity, enabling a shift from a neural stem cell-like program towards a profile of primary ependymoma tumor upon in vivo transplantation. Serial transplantation of DKFZ-EP1NS cells from orthotopic xenografts yielded secondary tumors in half the time compared with the initial transplantation. The cells were resistant to temozolomide, vincristine, and cisplatin, but responded to histone deacetylase inhibitor (HDACi) treatment at therapeutically achievable concentrations. In vitro treatment of DKFZ-EP1NS cells with the HDACi Vorinostat induced neuronal differentiation associated with loss of stem cell-specific properties. In summary, this is the first ependymoma model of a cytogenetic group 3 and molecular subgroup C ependymoma based on a human cell line with stem cell-like properties, which we used to demonstrate the differentiation-inducing therapeutic potential of HDACi.
Reference Key
milde2011actaa Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Till Milde;Susanne Kleber;Andrey Korshunov;Hendrik Witt;Thomas Hielscher;Philipp Koch;Hans-Georg Kopp;Manfred Jugold;Hedwig E. Deubzer;Ina Oehme;Marco Lodrini;Hermann-Josef Gröne;Axel Benner;Oliver Brüstle;Richard J. Gilbertson;Andreas von Deimling;Andreas E. Kulozik;Stefan M. Pfister;Ana Martin-Villalba;Olaf Witt;Till Milde;Susanne Kleber;Andrey Korshunov;Hendrik Witt;Thomas Hielscher;Philipp Koch;Hans-Georg Kopp;Manfred Jugold;Hedwig E. Deubzer;Ina Oehme;Marco Lodrini;Hermann-Josef Gröne;Axel Benner;Oliver Brüstle;Richard J. Gilbertson;Andreas von Deimling;Andreas E. Kulozik;Stefan M. Pfister;Ana Martin-Villalba;Olaf Witt;
Journal acta neuropathologica
Year 2011
DOI
doi:10.1007/s00401-011-0866-3
URL
https://link.springer.com/article/10.1007/s00401-011-0866-3
Keywords
pathology neurosciences

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.